# Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease

> **NCT04984330** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Weill Medical College of Cornell University**

## Conditions studied

- Amyloid
- Amyloidosis
- AL Amyloidosis

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04984330
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12
- **Primary completion:** 2023-06
- **Final completion:** 2024-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding withdrawn
- **Last updated:** 2022-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04984330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04984330, "Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04984330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*